abc biopply & Preclina: Collaboration to improve predictiveness of preclinical studies

The greatest limitation in drug development is still the transferability of results of preclinical studies to the subsequent efficacy and safety of clinical trials in humans. In order to improve this predictiveness, many efforts have been made in recent years to adapt preclinical models more and more closely to the conditions in human organisms. The two companies are innovation leaders in the field of preclinical in vitro and in vivo models with their respective technologies. The partnership will combine abc biopply’s expertise in humanized in vitro technologies with Preclina’s humanized in vivo capabilities. By applying the same standards, consistency in the use of materials and an integrated project organization and reporting, customers will receive an end-to-end solution for their studies and improved efficiency in the development of new drugs.

The companies will jointly promote their services, while all in vitro modules will be conducted by abc biopply’s organoid specialists and all in vivo modules will be handled by Preclina’s immune specialists. Future plans could include evaluating the licensing of parts of abc biopply’s in vitro services to Preclina’s labs to streamline project management even more and optimize servicing of global customers to the next level.

This strategic collaboration leverages the strengths of both companies to advance preclinical research and support the pharmaceutical, biotech, and medical device industries in their quest for innovative treatments and helping them de-risking their projects financially and time wise.